EGFR Inhibitors-Induced Skin Disorders Market to Observe Stupendous Growth During the Forecast Period (2023-2032) - DelveInsight | AstraZeneca, Pfizer, Novartis, Janssen, Takeda, AnaptysBio, TWi Pharmaceuticals, Azitra, AnaptysBio, Lutris Pharma

The EGFR Inhibitors-Induced Skin Disorders Market is evolving rapidly with the introduction of innovative topical and systemic treatments aimed at managing dermatologic side effects. Pharmaceutical companies are focusing on developing targeted therapies to alleviate symptoms such as rash, itching, and dry skin caused by EGFR inhibitors. Furthermore, advancements in supportive care and skincare regimens are enhancing patient comfort and adherence to treatment, reflecting a growing commitment to addressing the dermatologic challenges associated with EGFR inhibitor therapy.

DelveInsight's "EGFR Inhibitors-Induced Skin Disorders Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the EGFR Inhibitors-Induced Skin Disorders Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual EGFR Inhibitors-Induced Skin Disorders therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current EGFR Inhibitors-Induced Skin Disorders treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

EGFR Inhibitors-Induced Skin Disorders: An Overview
The epidermal growth factor receptor (EGFR) is a trans-membrane protein that regulates multiple cellular processes, including proliferation, differentiation, and survival, and is overexpressed in various solid cancerous tumors. The EGFR inhibitor class of targeted antitumor agents is designed to bind to the EGFR, thereby preventing its activation and downstream signaling cascade. EGFR inhibitors have emerged as a therapeutic standard against multiple malignancies, including colorectal cancer, squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), and metastatic breast cancer; and use of these agents is becoming increasingly widespread.

The antitumor activity of EGFR inhibitor agents as a class is primarily through blockade of the EGFR signaling pathway. Although the toxicity profile of EGFR inhibitors is generally favorable, patients receiving these agentsare often affected by dermatologic toxicities, namely acneiform (papulopustular) rash and, less commonly, nail changes, and/or paronychia. Patients may also experience xerosis, pruritus, flushing, telangiectasias, mucositis, and hair growth changes.

Among the cutaneous toxicities observed in cancer patients treated with EGFR inhibitors, the most common are the papulopustular rash of the upper trunk and face skin (60-90%), dry and itchy skin (12-16%), and microbial infections (38-70%). Less frequently, pruritus, hair modifications, and paronychial inflammation can occur.

Although side effects induced by EGFR inhibitors are generally classified as moderate, they are usually chronic and may significantly impact the patient's QoL and thus necessitate dose reduction or even interruption of treatment.

EGFR Inhibitors-Induced Skin Disorders Market Key Facts
• The EGFR Inhibitors-Induced Skin Disorders market size in the 7MM was estimated to be USD 57 million in 2020.
• The United States holds the largest market share of EGFR Inhibitors-induced Skin Disorders among the 7MM countries, which accounts for 49.59% (USD 28 million) of the total 7MM market, in 2020.
• Among the EU-5 countries, Germany (USD 5 million) had the highest market share, followed by France (USD 4 million) and Italy (USD 4 million), in 2020.
• Japan holds the second-largest share of the 7MM EGFR Inhibitors-induced Skin Disorders market with a market size of USD 9 million in 2020, which is expected to rise by 2032.
• The total number of cases of EGFR Inhibitors-induced Skin Disorders in the 7MM was 106,119 in 2020, which is likely to increase by 2032.
• In 2020, the total number of cases of cancer patients on EGFR inhibitors in the US was estimated to be 57,541, which is likely to increase by 2032.
• The total number of cases of EGFR Inhibitors-induced Skin Disorders in the US was 37,463 in 2020.
• Among the EU-5 countries, in 2020, the highest cases of EGFR Inhibitors-induced Skin Disorders were found in Germany (12,010), followed by France (9,632) and Italy (9,330); while Spain (7,716) accounted for the least number of cases.
• Japan accounted for 19.89% (21,102 cases) of total cases of EGFR Inhibitors-induced Skin Disorders among 7MM in 2020. These cases are expected to rise by 2032.

Get a Detailed Overview of the Evolving EGFR Inhibitors-Induced Skin Disorders Market Trends @
https://www.delveinsight.com/report-store/egfr-inhibitors-induced-skin-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

EGFR Inhibitors-Induced Skin Disorders Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging EGFR Inhibitors-Induced Skin Disorders therapies in the market. It also provides a detailed assessment of the EGFR Inhibitors-Induced Skin Disorders market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed EGFR Inhibitors-Induced Skin Disorders drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the EGFR Inhibitors-Induced Skin Disorders Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/egfr-inhibitors-induced-skin-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

EGFR Inhibitors-Induced Skin Disorders Epidemiology
The epidemiology section covers detailed insights into the historical, and current EGFR Inhibitors-Induced Skin Disorders patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the EGFR Inhibitors-Induced Skin Disorders Epidemiology Segmented as -
• Total Number of Cases of EGFR inhibitors by Cancer Type
• Total Cases of EGFR Inhibitors-induced Skin Disorders

Get Key Insights Into the Evolving EGFR Inhibitors-Induced Skin Disorders Epidemiology Trends @
https://www.delveinsight.com/report-store/egfr-inhibitors-induced-skin-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

EGFR Inhibitors-Induced Skin Disorders Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the EGFR Inhibitors-Induced Skin Disorders market or expected to be launched during the study period. The analysis covers the market share by EGFR Inhibitors-Induced Skin Disorders drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the EGFR Inhibitors-Induced Skin Disorders Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the EGFR Inhibitors-Induced Skin Disorders Market @
https://www.delveinsight.com/sample-request/egfr-inhibitors-induced-skin-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

EGFR Inhibitors-Induced Skin Disorders Therapeutics Assessment
The treatment of EGFR inhibitor-related skin reactions is not standardized, and accounts in the literature are based on local practice and mainly derived from personal, albeit extensive, experience. Currently, there is no approved therapy specific for anti-EGFR-induced skin diseases in the US, EU, Japan, and China. The off-label therapeutic options used for anti-EGFR induced skin diseases are sunscreen, emollients and soap substitutes, antibiotics, antihistamines, topical steroids, and cosmetics.

In contrast to acne vulgaris, topical antibiotic treatment with erythromycin, metronidazole, or nadifloxacin twice daily is recommended for early-stage and low-grade papulopustular skin reactions. Cream or lotion preparations are preferred to take advantage of an additional moisturization effect. Skin moisturizer and urea- or polidocanol-containing lotions are used to soothe pruritus. Fissures are treated topically with propylene glycol 50% in water for 30 min under plastic occlusion every night, followed by application of hydrocolloid dressing. Paronychia is treated with daily antiseptic baths to avoid bacterial superinfection.

Leading Companies in the EGFR Inhibitors-Induced Skin Disorders Therapeutics Market Include
• AstraZeneca
• Pfizer
• Novartis Pharmaceuticals
• Janssen Research & Development
• Yuhan Corporation
• Takeda
And Many Others

Emerging and Marketed EGFR Inhibitors-Induced Skin Disorders Therapies Covered in the Report Include
• Imsidolimab (ANB019): AnaptysBio Inc.
• AC-701 Topical Gel 0.3%: TWi Pharmaceuticals
• ATR-04: Azitra Inc.
• Imsidolimab (ANB019): AnaptysBio Inc.
• LUT014: Lutris Pharma Ltd.
• HT-001/WEG232 (Aprepitant): Hoth Therapeutics
And Many More

Learn More About the Emerging Therapies and key Companies in the EGFR Inhibitors-Induced Skin Disorders Therapeutics Market @
https://www.delveinsight.com/sample-request/egfr-inhibitors-induced-skin-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. EGFR Inhibitors-Induced Skin Disorders Competitive Intelligence Analysis
4. EGFR Inhibitors-Induced Skin Disorders Market Overview at a Glance
5. EGFR Inhibitors-Induced Skin Disorders Background and Overview
6. EGFR Inhibitors-Induced Skin Disorders Patient Journey
7. EGFR Inhibitors-Induced Skin Disorders Epidemiology and Patient Population
8. EGFR Inhibitors-Induced Skin Disorders Treatment Algorithm, Current Treatment, and Medical Practices
9. EGFR Inhibitors-Induced Skin Disorders Unmet Needs
10. Key Endpoints of EGFR Inhibitors-Induced Skin Disorders Treatment
11. EGFR Inhibitors-Induced Skin Disorders Marketed Products
12. EGFR Inhibitors-Induced Skin Disorders Emerging Therapies
13. EGFR Inhibitors-Induced Skin Disorders Seven Major Market Analysis
14. Attribute Analysis
15. EGFR Inhibitors-Induced Skin Disorders Market Outlook (7 major markets)
16. EGFR Inhibitors-Induced Skin Disorders Access and Reimbursement Overview
17. KOL Views on the EGFR Inhibitors-Induced Skin Disorders Market.
18. EGFR Inhibitors-Induced Skin Disorders Market Drivers
19. EGFR Inhibitors-Induced Skin Disorders Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/egfr-inhibitors-induced-skin-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.